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E-cadherin/CDH1 dysfunction is a well-established event in
GC initiation and progression in nearly 80% of gastric cancers
(GC), independently of histological type. While E-cadherin
permanent loss is the trigger for diffuse GC (DGC), transient
aberrant expression is common along progression in intestinal
GC (IGC). DGC has poorer prognosis than IGC and it spreads to
the peritoneum, while IGC metastasizes to distant organs. We
hypothesize that the timing (initiation vs progression) and mode
of E-cadherin loss of function (permanent vs persistent; complete
loss vs aberrant) determine the GC pattern of tumour spreading
and prognosis and therefore explored the underlying mecha-
nisms. The pattern of E-cadherin expression was analyzed by
immunohistochemistry and correlated with clinicopathological
features and overall survival (OS) in 284 patients. Permanent
(CRISPR-Cas9) and transient (RNAi) E-cadherin depleted cell
models representative of DGC and IGC were established and
characterized by RNA-sequencing and label-free quantitative
proteomics profiling followed by bioinformatics analysis. GC
presenting aberrant E-cadherin expression were more often IGC,
more advanced, more often spread to distant organs, and
displayed poorer prognosis than GC with complete E-cadherin
loss or normal E-cadherin expression. Remarkably, GCs with
absent/residual E-cadherin expression were more often DGC.
Proteomics and transcriptomic profiling revealed that transient
and permanent E-cadherin depletion in the DGC model
dramatically impairs cell-cell (adherens, tight juntions and
desmosomes), and cell-matrix adhesion. The same manipulations
in the IGC model led to cadherin-switch and downregulation of
adherens junction and cell motility proteins. Our study demon-
strates that E-cadherin dysfunction is associated with poor
prognosis. Our data supports the hypothesis that E-cadherin
transient loss in DGCgenerates an acute phenotype of cell-cell and
cell-matrix adhesion loss that persists and likely prevents spreading
to distant sites; while transient or permanent E-cadherin loss in
IGC likely triggers cell detachment and expression of alternative
cadherins allowing spreading to distant organs.
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Aims/Context: Machado-Joseph Disease (MJD) is a neurode-
generative disease associated with extensive neuronal death.
Defects in brain cholesterol metabolism may contribute to
neurodegenerative diseases. Brain cholesterol is almost exclu-
sively synthesized in situ and cannot cross the blood-brain-
barrier. To maintain the cholesterol homeostasis, superfluous
cholesterol is converted into 24S-hydroxycholesterol by the
neuronal enzyme cholesterol 24-hydroxylase (CYP46A1). The
present work evaluated i) whetherCYP46A1 levels are reduced in
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MJD, ii) ifCYP46A1 overexpression could improveMJD, and iii)
the mechanisms behind the observed recovery. Methods:
CYP46A1 levels were evaluated in cerebellar extracts of MJD
patients and in transgenic MJD mice cerebella. CYP46A1
overexpression effect was assessed in two MJD mouse models.
In the lentiviral-based mouse model, AAVrh10 encoding
CYP46A1 or GFP (control) were injected into the striatum of
C57BL6/J mice, and 2months post-injection the neuronal marker
DARPP32 levels andmutant ataxin-3 (mutAtxn3) inclusions’ size
and number were measured. Transgenic MJD mice were injected
into the cerebellum with AAVrh10 encoding CYP46A1 or GFP
and motor performance was evaluated. Then mice’s cerebella
were analyzed for mutAtxn3 inclusions, Purkinje cell numbers,
and cerebellar atrophy. Moreover, CYP46A1 potential activa-
tion of autophagy was evaluated in Neuro2A cells and in vivo.
Results: Our data indicate that CYP46A1 cerebellar levels are
decreased by 46% in MJD patients and by 29% in MJD mice.
CYP46A1 overexpression reduced DARPP32 loss (48%),
mutAtxn3 inclusion number by 59% and their size by 47%.
Significant alleviation of motor behavior impairments correlated
with mitigation of MJD-associated neuropathology, namely,
reduction of Purkinje cell loss (34%) and of cerebellar atrophy
(25.40% in lobule X) was observed. Finally, our work
demonstrated that CYP46A1 overexpression induces autophagy
(LC3B-II increase and p62 decrease) both in in vitro and in vivo
MJD models. Conclusions: Overall our results demonstrate that
CYP46A1 overexpression improves MJD-associated motor coor-
dination and neuropathology through autophagy enhancement.
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Introduction: CDH1 pathogenic germline variants cause Heredi-
tary Diffuse Gastric Cancer (HDGC), in less than half of patients/
families fulfilling clinical criteria.CDH1-negative cases often display
germlineCDH1monoallelic expression and somatic E-cadherin loss
of function.Wehypothesized thatCDH1-negativeHDGCmayarise
due to germline defects in CDH1 regulatory regions. Therefore, we
explored theCDH1 regulatory network to find expressionmodifier
sequences, controlling CDH1 expression, that could potentially
explain E-Cadherin loss of function phenotypes. Materials and
Methods: Capture Hi-C (cHi-C) with a viewpoint in CDH1
promoter was performed in 5 gastric cancer cell lines, either positive
or negative for E-cadherin expression. Mouse embryo reporter
assays were used to test a candidate regulatory region by cloning in
LacZ-reporter, integration into ColA1 locus of mouse embryonic
stem cells, and generation of transgenic mice. Empty-vector mice
were used as control for ColA1-driven expression. Tissue-specific
b-galactosidase expressionwas tested indissected tissues: stomach,
esophagus, duodenum, liver (endoderm), heart (ectoderm) and
skin (mesoderm). Results: We found evidence that CDH1
promotor interacts simultaneously with an intergenic region in
the short arm of chromosome 2 and an intronic region within
CDH1 intron 2. These interactions were specific of CDH1-
negative cell lines, highlighting a potential negative regulatory
network. We so far tested the regulatory potential of the CDH1
intronic region and found tissue-specific b-galactosidase expres-
sion in endodermal-derived tissues (stomach, esophagus and
duodenum), where E-cadherin exerts a primordial function.
Conclusion: We found a potential negative regulatory network
in gastric cancer cell lines through cis and trans interactions of the
CDH1 promoter, and evidence for its tissue-specific regulation in
the stomach. These findings suggest a novel mechanism triggering
E-cadherin loss of function, worth to be tested in HDGC patients
negative for CDH1 germline coding variants.
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Aims/Context: Primary cilia are specialized microtubule-based
signaling organelles that convey extracellular signaling and
cellular polarity into a cellular response. Defects in primary cilia
assembly/function cause severe diseases known as ciliopathies,
typified by clinical manifestations, as infertility, obesity, brain
problems, blindness and kidney cysts. Primary cilia assembly
entails centrosome migration to the plasma membrane where a
centriole docks, maturates into a basal body (BB), and assembles
the cilia axoneme. The human centrosomal TBCCD1 is a critical
factor in centrosome positioning previously identified by us. Our
aim is to discover the mechanisms/signals required for the correct
positioning of the centrosome during cilia assembly, and how
these mechanisms, when compromised, are related to ciliopa-
thies. Methods: The proximity-dependent identification (BioID)
assay was used to screen for TBCCD1 interactors. Immunofluo-
rescent and super resolution microscopy, as well as Western blot,
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